Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
Australian Market
Holding AU:TYP?
Track your performance easily

Tryptamine Therapeutics (TYP) Financial Statements

9 Followers

Tryptamine Therapeutics Financial Overview

Tryptamine Therapeutics's market cap is currently ―. The company's EPS TTM is AU$-0.013; its P/E ratio is -1.52; Tryptamine Therapeutics is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is AU$―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Jun 21Jun 20Jun 19
Income Statement-
Total Revenue----
Gross Profit----
EBIT----
EBITDA----
Net Income Common Stockholders----
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsAU$ 4.85MAU$ 12.72MAU$ 1.74MAU$ 4.42M
Total AssetsAU$ 13.61MAU$ 21.46MAU$ 6.54MAU$ 5.40M
Total DebtAU$ 3.74MAU$ 1.36MAU$ 912.87KAU$ 0.00
Net DebtAU$ -1.10MAU$ -11.37MAU$ -830.05KAU$ -4.42M
Total LiabilitiesAU$ 4.81MAU$ 2.59MAU$ 1.53MAU$ 281.00K
Stockholders EquityAU$ 8.81MAU$ 18.87MAU$ 5.02MAU$ 5.12M
Cash Flow-
Free Cash Flow----
Operating Cash Flow----
Investing Cash Flow----
Financing Cash Flow----
Currency in AUD

Tryptamine Therapeutics Earnings and Revenue History

Tryptamine Therapeutics Debt to Assets

Tryptamine Therapeutics Cash Flow

Tryptamine Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis